

## Safety Data Sheet

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

**Initial preparation date:** 16.07.2024

Page **1** of **13**

**Revision date:** 26.03.2025

### TRI-SOLFEN WOUND ANAESTHETIC & ANTISEPTIC SOLUTION

#### SECTION 1: Identification

##### Product identifier

**Product name:** TRI-SOLFEN WOUND ANAESTHETIC & ANTISEPTIC SOLUTION

**Synonyms:** TRI-SOLFEN WOUND

##### Recommended use of the product and restriction on use:

**Relevant identified uses:** VETERINARY USE. Local anaesthetic and antiseptic spray to provide pain relief.

**Uses advised against:** Not for human use.

**Reasons why uses advised against:** Veterinary product.

##### Manufacturer or supplier details

###### Supplier:

**Dechra Veterinary Products NZ Limited**

PO Box 1604,

Paraparaumu Beach, 5252

New Zealand

Phone: 0800 479 838

Email: [info.nz@dechra.com](mailto:info.nz@dechra.com)

Website: <http://www.dechra.co.nz/>

##### Emergency telephone number:

###### New Zealand

National Poisons Centre

0800 764 766

#### SECTION 2: Hazards identification

**Not Classified as a Dangerous Good according to NZS 5433:2012 Transport of Dangerous Goods on Land.**

**Classified in accordance with the Hazardous Substances (Hazard Classification) Notice 2020.**

**HSNO Classification or Subclasses – Physical hazards:** Not applicable

**HSNO Classification or Subclasses – Health hazards:**

Class	GHS Category	HSNO Category
Serious eye damage/eye irritation	Category 2	6.4A
Skin sensitization	Category 1	6.5B
Germ cell mutagenicity	Category 2	6.6B
Carcinogenicity	Category 2	6.7B
Specific target organ toxicity – repeated exposure	Category 2	6.9B

# Safety Data Sheet

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 16.07.2024

Page 2 of 13

Revision date: 26.03.2025

## TRI-SOLFEN WOUND ANAESTHETIC & ANTISEPTIC SOLUTION

### HSNO Classification or Subclasses – Environmental hazards:

Class	GHS Category	HSNO Category
Hazardous to the aquatic environment, chronic	Category 2	9.1B
Hazardous to terrestrial invertebrates	Not Applicable	9.3A; 9.3B; 9.3C

### GHS classification:

Eye Irritation, category 2  
Skin sensitization, category 1  
Germ cell mutagenicity, category 2  
Carcinogenicity, category 2  
Specific target organ toxicity – repeated exposure, category 2  
Chronic aquatic hazard, category 2

### Label elements

#### Hazard pictogram(s):



**Signal word:** Warning

#### Hazard statements:

H317 May cause an allergic skin reaction  
H319 Causes serious eye irritation  
H341 Suspected of causing genetic defects  
H351 Suspected of causing cancer  
H373 May cause damage to organs through prolonged or repeated oral exposure  
H411 Toxic to aquatic life with long lasting effects

#### Precautionary statements:

P201 Obtain special instructions before use  
P202 Do not handle until all safety precautions have been read and understood  
P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray  
P264 Wash any exposed skin thoroughly after handling  
P280 Wear protective gloves, protective clothing and eye protection  
P272 Contaminated work clothing should not be allowed out of the workplace  
P273 Avoid release to the environment  
P302+P352 IF ON SKIN: Wash with plenty of soap and water  
P333+P313 If skin irritation or rash occurs: Get medical advice/attention  
P321 Specific treatment (see Sections 4 – 8 of this SDS and any supplemental instructions on product label)  
P363 Wash contaminated clothing before reuse  
P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing  
P337+P313 If eye irritation persists: Get medical advice/attention  
P308+P313 IF exposed or concerned: Get medical advice/attention  
P314 Get medical advice/attention if you feel unwell  
P391 Collect spillage

# Safety Data Sheet

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

**Initial preparation date:** 16.07.2024

Page **3** of **13**

**Revision date:** 26.03.2025

## TRI-SOLFEN WOUND ANAESTHETIC & ANTISEPTIC SOLUTION

P405 Store locked up

P501 Dispose of contents and container in accordance with local, regional, national, and international regulations

**Hazards not otherwise classified:** None

### SECTION 3: Composition/information on ingredients

#### Mixture:

Identification	Name	Weight %
CAS number: 6108-05-0	Lignocaine hydrochloride	5
CAS number: 73360-54-0	Bupivacaine hydrochloride	0.5
CAS number: 8044-71-1	Cetrimide	0.5

#### Additional information:

The specific chemical identity and/or exact percentage (concentration) of composition has been withheld as a trade secret under the provisions of sections 55 (7) of the HSNO Act.

### SECTION 4: First-aid measures

**For advice, contact a Poisons Information Center (e.g. phone Australia 131 126, New Zealand 0800 764 766) or a doctor.**

#### Description of first aid measures

##### General notes:

Show this Safety Data Sheet to the doctor in attendance.

##### After inhalation:

If inhaled, remove person to fresh air and place in a position comfortable for breathing. Keep person at rest. If breathing is difficult, administer oxygen. If breathing has stopped, provide artificial respiration. If experiencing respiratory symptoms, seek medical advice/attention.

##### After skin contact:

Remove contaminated clothing and shoes. Rinse skin with copious amounts of water [shower] for several minutes. Launder contaminated clothing before reuse. If symptoms develop or persist, seek medical advice/attention.

##### After eye contact:

Rinse eyes with plenty of water for several minutes. Remove contact lenses if present and easy to do so. Protect unexposed eye. If symptoms develop or persist, seek medical advice/attention.

##### After swallowing:

If swallowed, DO NOT induce vomiting unless told to do so by a physician or poison control center. Rinse mouth with water. Never give anything by mouth to an unconscious person. If spontaneous vomiting occurs, place on the left side with head down to prevent aspiration of liquid into the lungs. If symptoms develop or persist, seek medical advice/attention.

# Safety Data Sheet

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

**Initial preparation date:** 16.07.2024

Page **4** of **13**

**Revision date:** 26.03.2025

## TRI-SOLFEN WOUND ANAESTHETIC & ANTISEPTIC SOLUTION

### Most important symptoms and effects, both acute and delayed:

#### Acute symptoms and effects:

Eye contact may result in irritation, redness, pain, inflammation, itching, burning and tearing.

Dermal exposure may cause an allergic skin reaction. Symptoms may include irritation, redness, pain, rash, inflammation, itching, burning and dermatitis.

#### Delayed symptoms and effects:

Exposure to Lignocaine hydrochloride may cause damage to organs through prolonged or repeated oral exposure.

Exposure to Lidocaine hydrochloride may cause genetic defects.

Lidocaine hydrochloride is a suspected human carcinogen. Exposure to Lidocaine hydrochloride may cause cancer.

### Immediate medical attention and special treatment:

#### Specific treatment:

Not determined or not applicable.

#### Notes for the doctor:

Treat symptomatically.

#### Workplace Facilities:

No additional information.

## SECTION 5: Fire-fighting measures

### Extinguishing media

#### Suitable extinguishing media:

Water mist/fog, carbon dioxide, dry chemical or alcohol-resistant foam.

#### Unsuitable extinguishing media:

Do not use water jet.

### Specific hazards during fire-fighting:

Thermal decomposition may produce irritating/toxic fumes/gases.

### Special protective equipment for firefighters:

Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full-face piece operated in positive pressure mode.

### Special precautions:

Avoid contact with skin, eyes, hair and clothing. Do not breathe fumes/gas/mists/aerosols/vapors/dusts.

Move containers from fire area if safe to do so. Use water spray/fog for cooling fire exposed containers.

Avoid unnecessary run-off of extinguishing media which may cause pollution.

### Hazchem or Emergency Action Code:

Not Applicable.

## SECTION 6: Accidental release measures

### Personal precautions, protective equipment and emergency procedures:

Evacuate unnecessary personnel. Ventilate area. Extinguish any sources of ignition. Wear recommended personal protective equipment (see Section 8). Do not get on skin, eyes or on clothing. Avoid breathing mist,

# Safety Data Sheet

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

**Initial preparation date:** 16.07.2024

Page **5** of **13**

**Revision date:** 26.03.2025

## TRI-SOLFEN WOUND ANAESTHETIC & ANTISEPTIC SOLUTION

vapor, dust, fume and spray. Do not walk through spilled material. Wash thoroughly after handling. Remove contaminated clothing and laundry before reuse.

### Environmental precautions:

Prevent further leakage or spillage if safe to do so. Prevent from reaching drains, sewers and waterways. Discharge into the environment must be avoided.

### Methods and material for containment and cleaning up:

Do not touch damaged containers or spilled material unless wearing appropriate personal protective clothing. Avoid breathing dust, mist, fumes, vapors or spray. Stop leak if you can do it without risk. Contain and collect spillage and place in suitable container for future disposal. Dispose of in accordance with all applicable regulations (see Section 13).

### Reference to other sections:

For personal protective equipment see Section 8. For disposal see Section 13.

## SECTION 7: Handling and storage precautions

### Precautions for safe handling:

Do not allow pregnant women or women trying to conceive to handle or use this product. Use appropriate personal protective equipment (see Section 8). Use only with adequate ventilation. Avoid breathing mist/vapor/spray/dust. Do not eat, drink, smoke, or use personal products when handling chemical substances. Avoid contact with skin, eyes and clothing. Wash affected areas thoroughly after handling. Keep away from incompatible materials (See Section 10). Keep containers tightly closed when not in use.

### Conditions for safe storage, including any incompatibilities:

Store in a cool, dry, well-ventilated location out of direct sunlight and away from exit paths. Inspect containers and storage area regularly for signs of leak and damage. Store containers at a convenient height for handling, below eye level if possible. High shelving increases the risk of dropping containers, personal injury and exposure. Ensure that appropriate fire fighting and spill-clean up equipment is readily available. Keep away from food and beverages. Protect from freezing and physical damage. Store away from heat, open flames and other sources of ignition. Store separately. Keep container tightly sealed. Store away from incompatible materials (See Section 10).

**Container Type:** HDPE

**Storage conditions:** Store below 30°C (room temperature). Do not store at low temperature.

### Safe packaging material

#### Suitable material:

HDPE

#### Unsuitable material:

Not determined or not applicable.

## SECTION 8: Exposure controls and personal protection

### Occupational Exposure limit values:

No occupational exposure limits noted for the ingredient(s).

### Biological limit value:

No biological exposure limits noted for the ingredient(s).

# Safety Data Sheet

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

**Initial preparation date:** 16.07.2024

Page **6** of **13**

**Revision date:** 26.03.2025

## TRI-SOLFEN WOUND ANAESTHETIC & ANTISEPTIC SOLUTION

### Information on monitoring procedures:

Not determined or not applicable

### Appropriate engineering controls:

Emergency eye wash stations and safety showers should be available in the immediate vicinity of use or handling. Provide adequate ventilation to maintain the airborne concentrations of vapor, mists, and/or dusts below the applicable workplace exposure limits, while observing recognized national standards (or equivalent).

### Personal protection equipment

#### Eye and face protection:

Safety glasses or goggles. Use eye protection equipment that has been tested and approved by recognized national standards (or equivalent).

#### Skin and body protection:

Chemical resistant, impervious gloves approved by the appropriate standards. Gloves must be inspected prior to use. Avoid skin contact with used gloves. Appropriate techniques should be used to remove used gloves and contaminated clothing. Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. Ensure that all personal protective equipment is approved by recognized national standards (or equivalent).

#### Respiratory protection:

If engineering controls do not maintain airborne concentrations below the applicable workplace exposure limits, or to an acceptable level (if exposure limits have not been established), a respirator approved by recognized national standards (or equivalent) must be worn.

### General hygienic measures:

When handling chemical products, do not eat, drink or smoke. Wash hands after handling, before breaks, and at the end of the workday. Avoid contact with skin, eyes and clothing. Wash contaminated clothing before reuse. Perform routine housekeeping.

## SECTION 9: Physical and chemical properties

<b>Appearance</b>	Clear, blue semi-viscous liquid
<b>Odour</b>	Slight odour
<b>Odour threshold</b>	Not determined or not available.
<b>pH</b>	2 to 3
<b>Melting point/freezing point</b>	Not determined or not available.
<b>Initial boiling point/range</b>	Not determined or not available.
<b>Flash point (closed cup)</b>	Not determined or not available.
<b>Flammability (solid, gas)</b>	Non flammable
<b>Upper flammability/explosive limit</b>	Not determined or not available.
<b>Lower flammability/explosive limit</b>	Not determined or not available.
<b>Vapour pressure</b>	Not determined or not available.
<b>Vapour density</b>	Not determined or not available.
<b>Relative density</b>	Not determined or not available.

# Safety Data Sheet

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 16.07.2024

Revision date: 26.03.2025

Page 7 of 13

## TRI-SOLFEN WOUND ANAESTHETIC & ANTISEPTIC SOLUTION

<b>Solubilities</b>	Soluble in water.
<b>Partition coefficient (n-octanol/water)</b>	Not determined or not available.
<b>Auto/Self-ignition temperature</b>	Not determined or not available.
<b>Decomposition temperature</b>	Not determined or not available.
<b>Kinematic viscosity</b>	Not determined or not available.
<b>Particle characteristics</b>	Not determined or not available.

**Other information:** No additional information.

## SECTION 10: Stability and reactivity

### Reactivity:

Not reactive under recommended handling and storage conditions.

### Chemical stability:

Stable under recommended handling and storage conditions.

### Possibility of hazardous reactions:

Hazardous reactions are not anticipated under recommended conditions of handling and storage.

### Conditions to avoid:

Avoid confined spaces, extreme heat, open flames, hot surfaces, sparks, ignition sources and incompatible materials.

### Incompatible materials:

None known.

### Hazardous decomposition products:

Under normal conditions of storage and use, hazardous decomposition products should not be produced.

## SECTION 11: Toxicological information

### Acute toxicity:

**Assessment:** Based on available data, the classification criteria are not met.

### Product data:

Route	Result
Oral ATE	LD50 Rat: 2202 mg/kg
Inhalation ATE	LC50 Rat: 27.25 mg/L (4 hr [dust/mist])
Dermal ATE	LD50 Rabbit: 20,000 mg/kg

### Substance data:

Name	Route	Result
Lignocaine hydrochloride	Oral	LD50 Mouse: 292 mg/kg
	Dermal ATE	LD50 Rabbit: 1100 mg/kg
	Inhalation ATE	LC50 Rat: 1.5 mg/L (4 hr [dust/mist])
Bupivacaine hydrochloride	Oral	LD50 Rabbit: 18 mg/kg

# Safety Data Sheet

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 16.07.2024

Revision date: 26.03.2025

Page 8 of 13

## TRI-SOLFEN WOUND ANAESTHETIC & ANTISEPTIC SOLUTION

Name	Route	Result
Cetrimide	oral	LD50 Rat: 1000 mg/kg
	Dermal ATE	LD50 Rabbit: 1100 mg/kg
	Inhalation ATE	LC50 Rat: 1.5 mg/L (4 hr [dust/mist])

### Skin corrosion/irritation

**Assessment:** Based on available data, the classification criteria are not met.

**Product data:** No data available.

#### Substance data:

Name	Result
Lignocaine hydrochloride	Causes skin irritation.
Cetrimide	Causes severe skin burns.

### Serious eye damage/irritation:

#### Assessment:

Causes serious eye irritation.

**Product data:** No data available.

#### Substance data:

Name	Result
Lignocaine hydrochloride	Causes serious eye irritation.
Cetrimide	Causes serious eye damage.

### Respiratory or skin sensitization:

#### Assessment:

May cause an allergic skin reaction.

**Product data:** No data available.

#### Substance data:

Name	Result
Cetrimide	May cause an allergic skin reaction.

### Carcinogenicity

#### Assessment:

Suspected of causing cancer.

**Product data:** No data available.

#### Substance data:

Name	Result
Lignocaine hydrochloride	Suspected of causing cancer.

**International Agency for Research on Cancer (IARC):** None of the ingredients are listed.

### Germ cell mutagenicity

#### Assessment:

Suspected of causing genetic defects.

**Product data:** No data available.



# Safety Data Sheet

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 16.07.2024

Page 9 of 13

Revision date: 26.03.2025

## TRI-SOLFEN WOUND ANAESTHETIC & ANTISEPTIC SOLUTION

### Substance data:

Name	Result
Lignocaine hydrochloride	Suspected of causing genetic defects.

### Reproductive toxicity

**Assessment:** Based on available data, the classification criteria are not met.

**Product data:** No data available.

**Substance data:** No data available.

### Specific target organ toxicity (single exposure)

**Assessment:** Based on available data, the classification criteria are not met.

**Product data:** No data available.

### Substance data:

Name	Result
Bupivacaine hydrochloride	May cause drowsiness or dizziness.

### Specific target organ toxicity (repeated exposure)

#### Assessment:

May cause damage to organs through prolonged or repeated exposure.

**Product data:** No data available.

### Substance data:

Name	Result
Lignocaine hydrochloride	May cause damage to organs through prolonged or repeated oral exposure.

### Aspiration toxicity

**Assessment:** Based on available data, the classification criteria are not met.

**Product data:** No data available.

**Substance data:** No data available.

### Information on likely routes of exposure:

Inhalation, oral, skin and eye contact.

### Symptoms related to the physical, chemical and toxicological characteristics:

See section 4 of this SDS.

### Other information:

No additional information.

## SECTION 12: Ecological information

### Ecotoxicity (aquatic and terrestrial)

#### Aquatic

##### Acute (short-term) toxicity

**Assessment:** Based on available data, the classification criteria are not met.

**Product data:** No data available.

# Safety Data Sheet

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 16.07.2024

Revision date: 26.03.2025

Page 10 of 13

## TRI-SOLFEN WOUND ANAESTHETIC & ANTISEPTIC SOLUTION

### Substance data:

Name	Result
Cetrimide	Fish LC50 Danio rerio: >1.81 mg/L (96 hr [Read-across substance data])
	Aquatic Invertebrates EC50 Daphnia magna: 0.022 mg/L (48 hr [Read-across substance data])

### Chronic (long-term) toxicity

**Assessment:** Based on available data, the classification criteria are not met.

**Product data:** No data available.

**Substance data:** No data available.

### Terrestrial

**Assessment:** Hazardous to terrestrial vertebrates.

**Product data:** No data available.

#### Substance data:

Name	Result
Lidocaine hydrochloride	Hazardous to terrestrial vertebrates.
Cetrimide	Hazardous to terrestrial vertebrates.

### Persistence and degradability

**Product data:** No data available.

#### Substance data:

Name	Result
Cetrimide	The substance is readily biodegradable.100% degradation in water, measured by DOC removal, after 7 days (Read-across substance data).

### Bioaccumulative potential

**Product data:** No data available.

#### Substance data:

Name	Result
Cetrimide	The substance is not expected to bioaccumulate (log Pow: 2.2 at 25 °C, Read-across substance data).

### Mobility in soil

**Product data:** No data available.

**Substance data:** No data available.

### Hazard to the ozone layer

**Product data:** No data available.

**Substance data:** No data available.

**Other adverse effects:** No additional information.

# Safety Data Sheet

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 16.07.2024

Page 11 of 13

Revision date: 26.03.2025

## TRI-SOLFEN WOUND ANAESTHETIC & ANTISEPTIC SOLUTION

### SECTION 13: Disposal considerations

#### Disposal methods:

It is the responsibility of the waste generator to properly characterize all waste materials according to applicable regulatory agencies. Dispose of in accordance with all applicable local, regional, state and federal regulations.

#### Contaminated packages:

Not determined or not applicable.

#### Disposal methods that should not be used:

No additional information.

### SECTION 14: Transportation information

#### Road/Rail transport: (NZS 5433:1999)

UN number	Not regulated
UN proper shipping name	Not regulated
UN transport hazard class(es)	None
Packing group	None
Environmental hazards	None
Special precautions for user	None

#### International Air Transport Association Dangerous Goods Regulations (IATA-ICAO)

UN number	Not regulated
UN proper shipping name	Not regulated
UN transport hazard class(es)	None
Packing group	None
Environmental hazards	None
Special precautions for user	None

#### International Maritime Dangerous Goods (IMDG)

UN number	Not regulated
UN proper shipping name	Not regulated
UN transport hazard class(es)	None
Packing group	None
Environmental hazards	None
Special precautions for user	None

Transport in bulk according to Annex II of MARPOL and the IBC Code: Not Applicable

# Safety Data Sheet

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 16.07.2024

Page 12 of 13

Revision date: 26.03.2025

## TRI-SOLFEN WOUND ANAESTHETIC & ANTISEPTIC SOLUTION

### SECTION 15: Regulatory information

#### New Zealand Inventory of Chemicals (NZIoC):

Bupivacaine hydrochloride

Not Listed

#### HSNO Classification or Subclasses:

Class	GHS Category	HSNO Category
Serious eye damage/eye irritation	Category 2	6.4A
Skin sensitization	Category 1	6.5B
Germ cell mutagenicity	Category 2	6.6B
Carcinogenicity	Category 2	6.7B
Specific target organ toxicity – repeated exposure	Category 2	6.9B
Hazardous to the aquatic environment, chronic	Category 2	9.1B
Hazardous to terrestrial invertebrates	Not Applicable	9.3A; 9.3B; 9.3C

#### HSNO Group Standard Name:

Veterinary Medicines (Non-dispersive Open System Application) Group Standard 2020

#### HSNO Approval Number:

HSR100759

**HSNO Controls:** Not determined.

**Approved handler test certificate:** Not determined.

**Tracking:** Not determined.

**Controlled substance license requirements:** Not applicable.

#### Agricultural Compounds and Veterinary Medicines Act 1997:

ACVM number

A011901

**Montreal Protocol (Ozone Depleting Substances):** None of the ingredients are listed.

**Stockholm Convention (Persistent Organic Pollutants):** None of the ingredients are listed.

**Rotterdam Convention (Prior Informed Consent):** None of the ingredients are listed.

**Basel Convention (Hazardous Waste):** None of the ingredients are listed.

### SECTION 16: Other information

#### Abbreviations and Acronyms:

<b>ATE</b>	Acute Toxicity Estimate
<b>BCF</b>	Bioconcentration Factor
<b>CAS</b>	Chemical Abstracts Service
<b>EC50</b>	Effective Concentration of 50%
<b>GHS</b>	Globally Harmonized System
<b>HSNO</b>	Hazardous Substances and New Organisms
<b>IARC</b>	International Agency for Research on Cancer
<b>IATA</b>	International Air Transport Association
<b>IBC</b>	Intermediate Bulk Container

# Safety Data Sheet

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 16.07.2024

Revision date: 26.03.2025

Page **13** of **13**

## TRI-SOLFEN WOUND ANAESTHETIC & ANTISEPTIC SOLUTION

<b>ICAO</b>	International Civil Aviation Organization
<b>IMDG</b>	International Maritime Dangerous Goods
<b>LC50</b>	Lethal Concentration 50%
<b>LD50</b>	Lethal Dose 50%
<b>MARPOL</b>	International Convention for the Prevention of Pollution from Ships
<b>NZIoC</b>	New Zealand Inventory of Chemicals
<b>TWA</b>	Time Weighted Average
<b>UN</b>	United Nations
<b>VOC</b>	Volatile Organic Compounds

### Disclaimer:

The information provided in this SDS is correct, to the best of our knowledge, based on information available. The information given is designed only as a guidance for safe handling, use, storage, transportation and disposal and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials, unless specified in the text. The responsibility to provide a safe workplace remains with the user.

Initial preparation date: 16.07.2024

Revision date: 26.03.2025

### Revision Notes:

Revision Date	Notes
26-03-2025	Version 2, supercedes Version 1 dated 16.07.2024

**End of Safety Data Sheet**